- Codexis Inc CDXS raised its guidance for 2021 following the receipt of a binding purchase order for up to $13.9 million of a proprietary high-performance enzyme product from an undisclosed pharmaceutical company.
- Now, the Company expects 2021 total revenues in the range of $89 million to $93 million, up from previous guidance of $82 million to $85 million, higher than the $83.7 million consensus.
- It expects product revenue in the band of $45 million to $48 million, compared to the earlier outlook of $36 million to $39 million.
- In addition, the Company also raised 2021 guidance for product gross margin to 60-64%, up from 54-58% guided earlier.
- HC Wainwright analyst Swayampakula Ramakanth maintained Codexis with a Buy and raised the price target from $26 to $27 (almost 40% upside).
- Price Action: CDXS shares closed at $19.64 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in